{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:48:04Z","timestamp":1788241684763,"version":"build-2803163510"},"reference-count":35,"publisher":"Ubiquity Press, Ltd.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,13]]},"DOI":"10.5334\/tohm.842","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T09:34:45Z","timestamp":1710322485000},"source":"Crossref","is-referenced-by-count":22,"title":["Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review"],"prefix":"10.5334","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-2894","authenticated-orcid":false,"given":"Mohadese","family":"Golsorkhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessa","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Pedouim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Frei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4447-2128","authenticated-orcid":false,"given":"Niloofar","family":"Bondariyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3547-0443","authenticated-orcid":false,"given":"Khashayar","family":"Dashtipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3285","reference":[{"key":"key20240315023518_B1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jns.2018.02.008","article-title":"The nosology of tardive syndromes","volume":"389","year":"2018","journal-title":"Journal of the neurological sciences"},{"key":"key20240315023518_B2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.parkreldis.2018.11.017","article-title":"Tardive dyskinesia: Who gets it and why","volume":"59","year":"2019","journal-title":"Parkinsonism & Related Disorders"},{"issue":"1","key":"key20240315023518_B3","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible Involvement of Free Radicals in Neuroleptic-Induced Movement Disorders Evidence from Treatment of Tardive Dyskinesia with Vitamin E","volume":"570","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"10","key":"key20240315023518_B4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.25107","article-title":"Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis","volume":"27","year":"2012","journal-title":"Movement Disorders"},{"issue":"3","key":"key20240315023518_B5","first-page":"20738","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","year":"2017","journal-title":"The Journal of clinical psychiatry"},{"key":"key20240315023518_B6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40120-018-0105-0","article-title":"Antipsychotic-related movement disorders: Drug-induced parkinsonism vs. tardive dyskinesia\u2014Key differences in pathophysiology and clinical management","volume":"7","year":"2018","journal-title":"Neurology and therapy"},{"key":"key20240315023518_B7","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1007\/s11136-019-02269-8","article-title":"Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia","volume":"28","year":"2019","journal-title":"Quality of Life Research"},{"key":"key20240315023518_B8","first-page":"3","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","year":"2013","journal-title":"Tremor and other hyperkinetic movements"},{"key":"key20240315023518_B9","doi-asserted-by":"crossref","first-page":"107580","DOI":"10.1016\/j.pharmthera.2020.107580","article-title":"VMAT2 inhibitors for the treatment of hyperkinetic movement disorders","volume":"212","year":"2020","journal-title":"Pharmacology & Therapeutics"},{"issue":"4","key":"key20240315023518_B10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0897190018756512","article-title":"VMAT2 Inhibitors for Tardive Dyskinesia\u2014Practice Implications","volume":"32","year":"2019","journal-title":"Journal of Pharmacy Practice"},{"issue":"5","key":"key20240315023518_B11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","year":"2017","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"key20240315023518_B12","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","year":"2017","journal-title":"The Lancet Psychiatry"},{"issue":"21","key":"key20240315023518_B13","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","year":"2017","journal-title":"Neurology"},{"issue":"11","key":"key20240315023518_B14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/pcn.13455","article-title":"Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT)","volume":"76","year":"2022","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"8","key":"key20240315023518_B15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/cns.12425","article-title":"A New VMAT-2 inhibitor NBI-641449 in the treatment of Huntington disease","volume":"21","year":"2015","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"6","key":"key20240315023518_B16","first-page":"328","article-title":"Valbenazine (Ingrezza): The first FDA-approved treatment for tardive dyskinesia","volume":"43","year":"2018","journal-title":"Pharmacy and Therapeutics"},{"key":"key20240315023518_B17","volume-title":"MPR Monthly Prescribing Reference","year":"2023"},{"key":"key20240315023518_B18","article-title":"Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations","year":"2023","journal-title":"Movement Disorders"},{"issue":"3","key":"key20240315023518_B19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ajhp\/zxz299","article-title":"Valbenazine and deutetrabenazine: vesicular monoamine transporter 2 inhibitors for tardive dyskinesia","volume":"77","year":"2020","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"8","key":"key20240315023518_B20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/mds.27769","article-title":"Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference","volume":"34","year":"2019","journal-title":"Movement Disorders"},{"key":"key20240315023518_B21","first-page":"3","article-title":"Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington\u2019s and other diseases","year":"2013","journal-title":"Tremor and Other Hyperkinetic Movements"},{"issue":"1","key":"key20240315023518_B22","article-title":"Valbenazine for the Treatment of Adults with Tardive Dyskinesia","volume":"9","year":"2021","journal-title":"Health Psychology Research"},{"key":"key20240315023518_B23","volume-title":"Treatment of hyperkinetic movement disorders","year":"2017"},{"issue":"4","key":"key20240315023518_B24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/schbul\/23.4.583","article-title":"Treatment of tardive dyskinesia","volume":"23","year":"1997","journal-title":"Schizophrenia Bulletin"},{"issue":"1024","key":"key20240315023518_B25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/pgmj.2010.103234","article-title":"Spectrum of tardive syndromes: clinical recognition and management","volume":"87","year":"2011","journal-title":"Postgraduate medical journal"},{"issue":"4","key":"key20240315023518_B26","first-page":"51","article-title":"Characteristics of Inpatients Prescribed Dopamine Receptor Blocking Agents","volume":"51","year":"2021","journal-title":"Psychopharmacology Bulletin"},{"issue":"12","key":"key20240315023518_B27","first-page":"690","article-title":"Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington\u2019s disease\u2013related chorea","volume":"33","year":"2008","journal-title":"Pharmacy and Therapeutics"},{"issue":"3","key":"key20240315023518_B28","first-page":"e202","article-title":"Evaluating depression and suicidality in tetrabenazine users with Huntington disease","volume":"91","year":"2018","journal-title":"Neurology"},{"issue":"9","key":"key20240315023518_B29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/mdc3.13849","article-title":"Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study","volume":"10","year":"2023","journal-title":"Movement Disorders Clinical Practice"},{"issue":"2","key":"key20240315023518_B30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"22","year":"2007","journal-title":"Movement disorders: official journal of the Movement Disorder Society"},{"key":"key20240315023518_B31","first-page":"3","article-title":"New generation VMAT2 inhibitors induced parkinsonism","year":"2020","journal-title":"Clinical Parkinsonism & Related Disorders"},{"key":"key20240315023518_B32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.parkreldis.2019.11.021","article-title":"Valbenazine-induced parkinsonism","volume":"70","year":"2020","journal-title":"Parkinsonism & Related Disorders"},{"issue":"9","key":"key20240315023518_B33","first-page":"e884","article-title":"Costs and utilization of new-to-market neurologic medications","volume":"100","year":"2023","journal-title":"Neurology"},{"key":"key20240315023518_B34","unstructured":"AUSTEDO\u00ae XR (deutetrabenazine) extended-release tablets, for oral use 2023\/02 [updated 02\/2023]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208082s000lbl.pdf."},{"key":"key20240315023518_B35","unstructured":"Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA\u00ae (valbenazine) Oral Granules Sprinkle Formulation 2023 [Available from: https:\/\/neurocrine.gcs-web.com\/news-releases\/news-release-details\/neurocrine-biosciences-announces-us-fda-accepts-new-drug]."}],"container-title":["Tremor and Other Hyperkinetic Movements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/storage.googleapis.com\/jnl-up-j-tohm-files\/journals\/1\/articles\/842\/65f3eb74093d5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:01:14Z","timestamp":1761552074000},"score":1,"resource":{"primary":{"URL":"https:\/\/tremorjournal.org\/articles\/10.5334\/tohm.842\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3,13]]}},"alternative-id":["10.5334\/tohm.842"],"URL":"https:\/\/doi.org\/10.5334\/tohm.842","relation":{},"ISSN":["2160-8288"],"issn-type":[{"value":"2160-8288","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"13"}}